Member of NSCLC Expert Committee of CSCO Member of Sarcoma Expert Committee of CSCO Member of the Youth Expert Committee of CSCO Member of Immunotherapy Expert Committee of CSCO Vice chairman of the National Committee of Young Experts on Clinical Application and Monitoring of Antineoplastic Drugs Standing member of Lung Cancer Committee of China Primary Health Care Foundation Standing Member of Professional Committee on Lung Cancer of Beijing Oncology Society Standing Member of Lung Cancer Immunotherapy Committee of Beijing Cancer Prevention and Control Society Member of Youth Committee of Oncology Society of Beijing Medical Association Key Members of the Innovation Team of the Ministry of Education Won the “National Natural Science Youth Fund”?“National Natural General Project”?“First Prize of Science and Technology Progress of Ministry of Education”, “Second Prize of National Science and Technology Progress” Long-term commitment to standardized individualized multidisciplinary comprehensive treatment and transformation of lung cancer-based thoracic tumors

Prof. Zhou studied medicine at NanTong Medical College and got the Ph.D at China Medical University in China. He got a fellow training in Tokyo National Chest Hospital for 2 years and worked as a visiting scientist for half an year at MD Anderson Cancer Center. In 1998, Prof Zhou moved to Shanghai and got a position as professor and director in the Department of Medical Oncology at Shanghai Pulmonary Hospital. He has more than 30 years of experience in clinical oncology with his main research interests focusing on early detection, molecular targeted therapy, and immunotherapy in lung cancer. Prof Zhou has published over 200 articles in international peer review journals, including the Lancet Oncology, Lancet Respiratory Medicine and Journal of Clinical Oncology. He is also involved in several professional societies, including associate editor of IASLC Newsletter, IASLC, chairmen of the NSCLC expert society in Chinese Society of Clinical Oncology (CSCO) and chairman of Thoracic Oncology Society in CPAM. He actively involved in IASLC meetings, including WCLC, APLCC, ELCC etc. In addition, he is the Editor-in-Chief of the Translation Lung Cancer Research, the Associate Editor of the Lung Cancer and serves on the Editorial Board of several other major oncology journals.

Dr. Tetsuya Mitsudomi joined the Board of Directors of IASLC in 2011 and has served as its board president since 2019. IASLC awarded Dr. Mitsudomi its Mary J. Matthews Pathology/Translational Research Award in 2013 for a lifetime achievement in pathology and translational research of thoracic malignancies. Dr. Mitsudomi has served as a professor in the Division of Thoracic Surgery at Kindai University Faculty of Medicine in Osaka, Japan since 2012. Prior to his current role, Dr. Mitsudomi worked as Chief of the Department of Thoracic Surgery at Aichi Cancer Center for 16 years after he served as an associate professor and vice director of the Kyushu University Hospital. His research focuses on the surgical treatment of lung cancer and individualized treatment of lung cancer based on cancer genotypes such as EGFR mutations and ALK translocations. He has published more than 400 papers that have been featured in international peer-reviewed journals. Dr. Mitsudomi earned his medical degree and his Ph.D. at Kyushu University Faculty of Medicine in Fukuoka, Japan. He completed his residency in surgery at Kyushu University Hospital and was a visiting fellow at the National Cancer Institute-Navy Medical Oncology Branch in Bethesda, Maryland from 1989 to 1991.

Viola Zhu is an Associate Clinical Professor of Medicine at the University of California Irvine and an attending physician at the Chao Family Comprehensive Cancer Center. She earned her medical degree from Fudan University Shanghai Medical College (former Shanghai Medical University) and was in a graduate program in Medical Oncology at the Fudan University Shanghai Cancer Center prior to receiving her PhD degree in Molecular Pathology and Immunology from the University of Medicine and Dentistry of New Jersey. She completed her residency in Internal Medicine at Englewood Hospital and Medical Center and fellowship in Hematology and Oncology at Boston Medical Center. She is board certified in Internal Medicine, Hematology, and Medical Oncology. Her clinical focus is lung cancer, and she is actively involved in many early phase trials of novel targeted therapies. She is on the editorial board for Journal of Clinical Oncology and has publications at many journals with high impact factor including New England Journal of Medicine, Journal of Clinical Oncology, and Cancer Discovery.

Dr. Yu is a Assistant Attending and Section Head of Molecular Targets in the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center. She oversees the EGFR-mutant lung cancer research program at MSKCC.

John Wrangle is a thoracic medical oncologist at the Medical University of South Carolina in Charleston studying the role of common gamma chain agonist cytokines in immunotherapy for solid tumors.

Dr. Antoinette Wozniak is a Professor of Medicine and Interim Chief of the Division of Hematology / Oncology, University of Pittsburgh. She is the Associate Director for Clinical Research, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania. Having relocated to Pittsburgh after working at the Karmanos Cancer Center in Detroit for most of her career.

Dr. Wozniak has over 30 years of experience in clinical trials, both in a primary role and as a co-investigator. This includes national trials from the Southwest Oncology Group, NCI sponsored studies and pharmaceutical trials. The focus of Dr. Wozniak’s clinical research has been in lung cancer (small cell and non-small cell), mesothelioma and thymus gland cancer.

Dr. Wozniak received her undergraduate degree from Niagara University, summa cum laude and completed her medical degree at the State University of New York at Buffalo. Dr. Wozniak completed her residency at SUNY at Buffalo and fellowship at the University of Florida. Prior to coming to Pittsburgh, Dr. Wozniak was a Professor of Oncology and served as Leader of the Lung Cancer Team and Co-Director of the Division of Hematology and Oncology at Wayne State University and the Karmanos Cancer Institute, Detroit, Michigan. She has over 200 publications and abstracts. She is very active in the American Society of Clinical Oncology, Southwest Oncology Group, American Lung Asssociation, and the Lung Cancer Research Foundation.

James W. Welsh, MD, is a Tenured Physician Scientist at The University of Texas MD Anderson Cancer Center. At MD Anderson he is the head of the immune radiation program, with has the goal of using radiation to turn the tumor into an

Assoc Prof @ UNC. Section chief of thoracic and head/neck. VP Cancergrace.org

Dr. Wakelee is the President-Elect of the IASLC. She serves as the Division Chief of Medical Oncology at Stanford University and is the Deputy Director of the Stanford Cancer Institute. Her research focuses broadly on lung cancer and thymic malignancies but is particularly focused on systemic therapy for early stage lung cancer and targeted therapy for driver mutation positive NSCLC.